CD8A and melanoma: In light of ongoing clinical trials of adjuvant anti-PD-1 therapy in stage II melanoma and the recent approval by the FDA for adjuvant pembrolizumab for stage II melanoma (5), investigating these CD8+ T cell populations within the context of primary melanoma immunotherapy is of great interest.